Alzheimer's Disease Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • ID: 4340304
  • Report
  • 254 pages
  • P&S Market Research
1 of 3
Pipeline Overview

Alzheimer’s disease is a progressive brain disorder that gradually destroys thinking skills and memory, and ultimately the capability to carry out the basic tasks. Alzheimer's disease is presently ranked as the third leading cause of death in the aging population, after heart disease and cancer. Alzheimer’s is the most common form of dementia among elder adults. Dementia is the loss of behavioral abilities and cognitive functioning which results in interference with a person’s daily life and activities and can range from severe to the mild stage. As the disease progresses, protein formation take place in the brain to form structures called 'tangles' and 'plaques'. This results in the loss of networks between nerve cells and ultimately leads to the death of nerve cells and damage to brain tissue. Lack of some important chemical messengers has also been observed in patients suffering from Alzheimer's disease. These chemical messengers communicate by sending signals around the brain. When there is a lack of these messengers, the signals are not transmitted efficiently.

Alzheimer’s is an intricate disease and it is not possible that any therapy or one drug can successfully treat it. Current approaches include helping people to maintain mental function, manage behavioral symptoms and slow or delay the symptoms of disease. The marketed drugs are available to reduce symptoms and improve quality of life fall under cholinesterase inhibitors class and include Donepezil, Alantamine, Rivastigmine and Tacrine.

Although significant progress has been witnessed in drug development for Alzheimer’s disease, studies are focused on various promising targets including amyloid beta protein, tau protein, beta secretase and 5-hydroxytryptamine 6 (5HT6) receptor with high potential, and reduced or no side effects. The cause for Alzheimer’s is still unknown, even after promising growth in the development of its pipeline. Also, specific targeted treatments are still not available in the market due to the unknown cause and inefficient diagnostic methods for early detection.

Pipeline Analysis

As of March 2017, the Alzheimer’s disease pipeline comprises of approximately 89 active drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for Alzheimer’s disease include Eli Lilly and Company, Genentech, Inc., and Eisai Co., Ltd and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
  • Market Forecast - Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Alzheimer’S Disease Pipeline Analysis
4.4.1 Pipeline Analysis By Phase
4.4.2 Pipeline Analysis By Target
4.4.3 Pipeline Analysis By Route Of Administration
4.4.4 Pipeline Analysis By Company

5. Alzheimer’S Disease Pipeline Analysis By Phase (2017)
5.1 Phase Iii: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Ii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Pre-Clinical: Drug Profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Strategic Development
5.4.4 Designation
5.4.5 Grants
5.4.6 Patent
5.4.7 Technology
5.5 Discovery: Drug Profiles
5.5.1 Strategic Development
5.5.2 Designation
5.5.3 Grants
5.5.4 Patent
5.5.5 Technology

6 Competitive Landscape
6.1 Benchmarking Of Alzheimer's Disease Drug Candidates Of Key Players
6.2 Swot Analysis Of Alzheimer's Disease Pipeline

7 Company Profiles
7.1 Business Overview
7.2 Product And Service Offerings

8 Appendix
8.1 Abbreviations

List Of Tables
Pipeline Analysis Of Alzheimer’S Disease, By Company (2017)
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Companies- At A Glance

List Of Figures
Research Methodology For The Alzheimer's Disease Pipeline Analysis
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Number Of Alzheimer’S Disease Drug Candidates Under Development (2017)
Alzheimer’S Disease Pipeline Split, By Target (2017)
Alzheimer’S Disease Pipeline Split, By Route Of Administration (2017)
Benchmarking Of Alzheimer's Disease Drug Candidates Of Key Players
Swot Analysis Of Alzheimer's Disease Pipeline
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll